Advanced Bioscience Laboratories, Inc.
Advanced Bioscience Laboratories, Inc. (ABL), doing business as Advanced Bioscience Laboratories Inc., is a leading contract research and manufacturing organization specializing in the development of gene therapies, vaccines, oncolytics, and immunotherapies. As a foreign-owned, for-profit manufacturer of goods, ABL provides a wide range of preclinical and clinical development services to support infectious disease research and product development initiatives for government agencies, academic institutions, and industry clients. The company's expertise spans biologics manufacturing, testing, storage, shipping, and quality assurance services. ABL has been awarded numerous federal contracts and grants, particularly from the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), to advance the development of medical countermeasures for various infectious diseases and other health conditions.
Through its federal contract awards, ABL has provided a diverse array of goods and services to support preclinical and clinical development programs. These include cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management for infectious disease countermeasures such as HIV, influenza, and other vaccines and therapeutics. ABL has performed work for multiple NIH institutes, including the National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), and National Institute of Neurological Disorders and Stroke (NINDS). The company has contributed to various programs, including HIV microbicides and biomedical prevention, pediatric drug formulation development, and cancer prevention initiatives. Notable projects include the manufacture of glycopeptide immunogen nanoparticle vaccines, development of bitter taste receptor blockers for pediatric medicines, and production of vaccines targeting frame-shift mutations in tumors. ABL's contracts typically do not have set-aside designations, reflecting its status as a large business in the federal contracting landscape.
ABL's involvement in federal grant programs has primarily been as a subcontractor to academic institutions. The company has supported grants focused on vaccine development and immunology studies. For instance, ABL has worked on a project to develop MecVax, a cross-protective subunit vaccine for enterotoxigenic E. coli (ETEC), in collaboration with the University of Illinois. Another significant grant-funded project involved toxicology studies and assay verification for a gonococcal peptide vaccine (TMCP2) in partnership with the University of Massachusetts Medical School. In these projects, ABL's role typically includes conducting toxicology studies, verifying immunological assays such as ELISAs and bactericidal assays, and providing technical expertise in vaccine development and testing.
ABL holds several Indefinite Delivery Vehicles (IDVs) with federal agencies, demonstrating its broad capabilities in biopharmaceutical research and development. A notable IDV is with NIAID for the Diagnostics Pre-Clinical Services Program, valued at $24 million, which supports in vitro diagnostic development. Another significant IDV is with NINDS for Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders, with a ceiling of $149.2 million. ABL also holds an IDV with NIAID for Resources to Advance Pediatrics and HIV Prevention Science, valued at $98.9 million, covering a range of preclinical development support services. Additionally, the company has an IDV with NCI for the PREVENT Cancer Preclinical Drug Development Program, focused on cGMP production of vaccines and biologicals for cancer prevention. These IDVs collectively demonstrate ABL's comprehensive capabilities in supporting the development of vaccines, therapeutics, and diagnostics across multiple disease areas and federal health agencies.
MK4QC9EKZXG8 541714
Not listed 9800 Medical Center Dr, Rockville, MD 20850, USA
10/5/06 2/6/26 Resilience Government Services, Inc.
Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., is a technology focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, Resilience aims to build a sustainable network of high tech, end to end manufacturing solutions to ensure the medicines of today and tomorrow are reliably supplied.
Through past federal contract awards, Resilience Government Services has provided a range of goods and services related to chemical and biological defense programs, medical countermeasure development, and pharmaceutical manufacturing. As a prime contractor, Resilience has conducted clinical trials, process development and validation, storage and stability testing, prototype development, and manufacturing scale-up across various task orders and contracts with the Department of Defense, specifically the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense, as well as the Department of Health and Human Services National Institutes of Health. Resilience has provided deliverables spanning early stage research through late stage product development, with the goal of achieving FDA licensure for medical countermeasures against biological threats and COVID-19. No set aside designations were indicated on the prime contract awards.
Resilience Government Services currently holds two active Indefinite Delivery Vehicles from the Department of the Army's Acquisition Support Center. A $5.7 million Other Transaction IDIQ aims to transfer existing capabilities to Resilience to demonstrate the provision of medical countermeasures. A $249 million single-award Indefinite Delivery Contract provides an acquisition vehicle for FDA-approved products supporting chemical and biological defense programs. Associated task orders under the IDC advance development and testing of a monoclonal antibody countermeasure through clinical trials and regulatory approval processes.
GC2RFAZK8G64 325412
Not listed 13200 Nano Ct, Alachua, FL 32615, USA
1/31/02 2/20/26 Dynport Vaccine Company LLC
Dynport Vaccine Company LLC DVC Segment Division is a subsidiary of General Dynamics Corp. that provides a range of research, development, manufacturing, and testing services to support biopharmaceutical products targeting infectious diseases.
Through past federal contracts, Dynport has provided preclinical development, clinical trials, diagnostic testing, vaccine stability evaluations, and cGMP production services in support of therapeutics and vaccines for emerging infectious diseases. Major customers include NIH, HHS, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. Prime contract awards have funded process development, assay validation, pilot manufacturing, Phase I trials, and stability testing of vaccine candidates over 1-5 year periods. Subcontracts have supported clinical trials and CGMP cell bank production. Most awards utilize firm fixed price or cost plus fixed fee structures without set asides. Places of performance are centered at Dynport's Maryland-based locations.
Dynport holds several infectious disease-focused IDVs as a prime contractor, most notably the $30 million Preclinical Services for Biopharmaceutical Product Development contract from NIH-NIAID. This single-award IDIQ covers process development, assay validation, CGMP production, and regulatory documentation to support candidate vaccines and therapies from early inception through preclinical advancement. Dynport also holds the $36 million Diagnostic Pre-Clinical Services Program contract, which funds development processes needed to bring candidate infectious disease diagnostics to market. Additionally, Dynport is one of multiple awardees under the $346 million Early Phase Clinical Trial Units IDIQ, which has funded Phase I trial services under cost plus fixed fee delivery orders to date.
LXNEGTYDR755 541714
Not listed 110 Thomas Johnson Dr, Frederick, MD 21702, USA
4/2/02 12/4/25